Suramin exerts in vivo cytokine modulatory properties on splenocytes from experimental allergic encephalomyelitis-induced SJL mice: Implications for autoimmune disease therapy

Immunopharmacology

Volumn 35, Issue 2, 1996, Pages 155-162

  Novales Li, Philipp ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

experimental allergic encephalomyelitis; interferon ; interleukin 4; suramin

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 4; SURAMIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; FEMALE; IMMUNIZATION; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE;

ANIMALS; CYTOKINES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; INTERFERON TYPE II; INTERLEUKIN-4; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED STRAINS; SPLEEN; SURAMIN; T-LYMPHOCYTES;

EID: 0030297704     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(96)00141-5     Document Type: Article

References (33)

1. Alzani, R., Corti, A., Grazioli, L., Cozzi, E., Ghezzi, P. and Marcucci, F., 1993. Suramin induces deoligomerization of human tumor necrosis factor alpha. J. Biol. Chem., 268; 12526-12529.
2. Baumann, H. und Strassmann, G., 1993. Suramin inhibits the stimulation of acute phase plasma protein genes by IL-6 type cytokines in rat hepatoma cells. J. Immunol., 151: 1456-1462.
3. Brandely, M., Lagrange, P.H. and Hurtrel, B., 1996. Effects of suramin on the in vivo antimicrobial resistance against Listeria monocytogenes and Mycobacterium bovis (BCG) in mice. Clin. Expt. Immunol., 63: 118-126.
4. Broder, S., Collins, J.M., Markham, P.D., Redfield, R.R., North, D.E., Groognan, J.F., Gallo, R.C., Yarchoan, R., Lane, H.C., Kloecker, R.W., Mitsuya, H., Gelmann, E., Resnick, L., Myers, C.E. and Fauci, A.S., 1985. Effects of suramin on HTLV-III/LAV infection presenting as Kaposi sarcoma or AIDS related complex: clinical pharmacology and suppression of virus replication in vivo. Lancet, 2: 627.
5. Carobbi, A., DiStefano, R., Danesi, R., Carmellini, M., Ferrari, M., Galatioto, C., Ermini, M. and Mosca, F., 1992. Suramin as an anticomplementary agent in xenotransplantation. Transpl. Proc., 24: 700.
6. Cher, D. and Mosmann, T.R., 1987. Two types of murine helper T cell clone. II. Delayed-type hypersensitivity is mediated by Th1 clones. J. Immunol., 138: 3688-3694.
7. Cogan, D.C., Cotter, S.M. and Kitchen, L.W., 1986. Effect of suramin on serum viral replication in feline leukemia virus-infected pet cats. Am. J. Vet. Res., 47: 2230-2232.
8. Correale, J., Gilmore, W., McMillan, M., Li, S., McCarthy, K., Le, T. and Weiner, L.P., 1995. Paterns of cytokine secretion by autoreactive proteolipid protein-specific T cell clones during the course of multiple sclerosis. J. Immunol., 154: 2959-2966.
9. Czernin, S., Gesel, A., Wilfing, A., Holler, W., Trieb, K., Waldhansi, W., Vierhapper, H., Forster and O., Grubeck-Loebenstein, B., 1993. Suramin affects human peripheral blood mononuclear cells in vitro: inhibition of T cell growth and modulation of cytokine secretion. Int. Arch. Allergy Immunol., 101: 240-246.
10. Denes, L., Hajos, G., Szporny, L., Szende, B., Lapis, K., Sipka, S. and Szegedi, G., 1987. The effect of thymopoietin 32-34 (TP3) on suramin-induced inhibition on delayed type hypersensitivity in guinea pigs. Immunol. Invest., 16: 275-279.
11. Eeftinck-Schattenkerk, J.K., Danner, S.A., Lange. J.M., Paul, D.A., van Boxtel, C.J., Miedema, F., Schellenkens, P.T. and Goudsmit, J., 1988. Persistence of human immunodeficiency virus antigenemia in patients with the acquired immunodeficiency syndrome treated with a reverse transcriptase inhibitor, suramin. Arch. Int. Med., 148: 209-211.
12. Gajewski, T.F., Schell, S.R., Nau, G. and Fitch, F.W., 1989. Evidence implicating utilization of different T cell receptor-associated signalling pathways by Th1 and Th2 clones. Immunol. Rev., 111: 79-110.
13. Gautam, S.C., Chikkala, N.F. and Hamilton, T.A., 1992. Anti-inflammatory action of interleukin-4. Negative regulation of contact sensitivity to trinitrochlorobenzene. J. Immunol., 148: 1411-1415.
14. Ghosh, J. and Miller, R.A., 1993. Suramin, an experimental chemotherapeutic drug, irreversibly blocks T cell CD45-protein tyrosine phosphatase in vitro. Biochem. Biophys. Res. Commun., 36-44.
15. Hawking, F., 1940. Concentration of Bayer 205 (Germanin) in human blood and CSF after treatment. Trans. R. Soc. Trop. Med. Hyg., 34: 87.
16. Kaplan, L.D., Wolfe, P.R., Volberding, P.A., Feorino, P., Levy, J.A., Abrams, D.I., Kiprov, D., Wong, R., Kaufman, L. and Gottlieb, M.S., 1987. Lack of response to suramin in patients with AIDS and AIDS-related complex. Am. J. Med., 82: 615-620.
17. Kessler, H.A., Pottage, J.C., Trenholme, G.M., Benson, C.A. and Levin, S., 1986. Effects of suramin on in vitro HBsAg production by PLC/PRF/5 cells and hepatitis B virus DNA polymerase activity. AIDS Res., 2: 63-72.
18. LaPushin, R., Totpal, K., Higuchi, M, and Aggarwal, B.B., 1994. Suramin inhibits tumor cell cytotoxicity mediated through natural killer cells, lytnphokine-activated killer cells, monocytes, and tumor necrosis factor. J. Clin. Immunol., 14: 39-49.
19. Mitsuya, H., Popovic, M., Yarchoan, R., Matsushita, S., Gallo, R.C. and Broder, S., 1984. Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. Science, 226: 172-174.
20. Mosmann, T.R., Cherwinski, H., Bond, M.W., Giedlin, M.A. and Coffman, R.L., 1986. Two types of murine helper T cell clone. I. Definitions according to profiles of lymphokine activity and secreted proteins. J. Immunol., 136: 2348-2357.
21. Novak, T.L. and Rothenberg, E.V., 1990. cAMP inhibits induction of interleukin-2 but not of interleukin-4 in T cells. Proc. Natl. Acad. Sci. USA, 87: 9353-9357.
22. Novales-Li, P. In vitro immunopharmacologic effect of suramin on modifying Th-subset levels in splenocytes and T cell clones. Immunol. Lett., in press.
23. Pace, J., Russell, S., LeBlanc, P. and Murasko, D., 1985. Comparative effects of various classes of mouse interferons on macrophage activation for tumour cell killing. J. Immunol., 134: 977-981.
24. Pesce, C.D., Ciprani, F., Donofrio, C., Alvino, E., Perno, C.F., Bonmassar, E. and Calio, R., 1987. Low concentrations of suramin can reduce in vitro infection of human blood lymphocytes with HTLV-I during long-term culture. Antiviral Res., 8: 247-260.
25. Reder, A.T., Thapar, M., Sapugay, A.M. and Jensen, M.A., 1994. Prostaglandins and inhibitors of arachidonate metabolism suppress experimental allergic encephalomyelitis. J. Neuroimmunol., 54: 117-128.
26. Reynolds, D., Boom, W. and Abbas, A., 1987. Inhibition of B lymphocyte activation by interferon-gamma. J. Immunol., 139: 767-773.
27. Shenoy, M., MacPherson and B., Christadoss, P., 1992. Suramin inhibits the mixed lymphocyte reaction by suppressing lymphokine production. J. Clin. Immunol., 12: 122-129.
28. Strassmann, G., Fong, M., Freter, C.E., Windsor, S., D'Allesandro, F. and Nordan, R.P., 1993. Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo. J. Clin. Invest., 92: 2152-2159.
29. van der Veen, R.C., Asghar, S.S., Uitdehaag, B.M., van der Helm, H.J. and Hommes, O.R., 1985. Suppression of the development of experimental allergic encephalomyelitis by suramin. Neuropharmacol., 24: 1139-1142.
30. van der Veen, R.C. and Stohlman, S.A., 1993. Encephalitogenic Th1 cells are inhibited by Th2 cells with related peptide specificity. Relative roles of interleukin (IL)-4 and IL-10. J. Neuroimmunol., 48: 213-220.
31. van der Veen, R.C., Trotter, J.L., Hickey, E.F. and Kapp, J.A., 1990. The development and characterization of encephalitogenic T cells specific for myelin proteolipid protein. J. Neuroimmunol., 26: 139-145.
32. Wagner, F., Fischer, N., Lersch, C., Hart, R. and Dancygnier, H., 1989. Interleukin-4 inhibits interleukin 2-induced production of its functional antagonist, interferon gamma. Immunol. Lett., 21: 237-241.
33. Yarchoan, R., Mitsuya, H., Matsushita, S. and Broder, S., 1985, Implications of the discovery of HTLV-III for the treatment of AIDS. Cancer Res., 45: 4685s-4688s.